A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime/GOG-3076 Study)
- Sponsor:
- Genelux Corporation
- Sponsor Study ID:
- 01182022GNLX
- CTO #:
- 103683
- NCT Number:
- NCT05281471
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Ovary
- Study Objectives:
- The primary objective is to determine Progression-free Survival (PFS) by RECIST 1.1. To determine Objective Response Rate (ORR) and Duration of Response (DOR) by RECIST 1.1, PFS by RECIST 1.1 (in modified population), PFS by iRECIST, Overall Survival (OS), and safety.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Orr, Brian, at orrb@musc.edu .
- Study Coordinator, Knox, Crystal, at knoxc@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina